What Clinical Evidence Says About Wegovy And Hair Loss
Understanding Wegovy And Hair Loss: UK Clinical Evidence
When researching Wegovy and hair loss, it's essential to distinguish between hair changes related to gradual weight management and direct medication effects. The comprehensive STEP clinical trials, which led to MHRA approval of Wegovy in the UK, monitored thousands of patients for adverse events including hair loss. In the pivotal STEP 1 trial published by Wilding et al. in the New England Journal of Medicine 2021, hair loss was reported as an uncommon side effect, occurring in less than 2% of patients taking Wegovy. Most importantly, hair changes associated with significant weight loss are typically temporary and usually mild and transient in nature.
The relationship between Wegovy and hair loss must be understood within the context of the substantial weight loss results achieved in clinical trials. When patients lose approximately 15% of their body weight over 68 weeks, as demonstrated in STEP 1, temporary hair thinning can occur due to the physiological stress of weight change rather than the medication itself. This phenomenon, known as telogen effluvium, is well-documented with any form of significant weight loss and typically resolves within 3-6 months as the body adjusts to its new weight.
Wegovy Pricing And Value For UK Patients Concerned About Hair Loss
At EverydayMeds, we understand that concerns about Wegovy and hair loss shouldn't prevent you from accessing proven weight management treatment. Our transparent pricing starts with the 0.25mg starter dose at £79.99, with new customer discount code FIRST40 applied at checkout to reach this final price. For patients wanting continuous supply during the crucial escalation phase, our Intro Trio bundle (0.25mg, 0.5mg & 1mg) provides three months of treatment for £299.99, ensuring you maintain momentum without supply interruptions.
Returning customers benefit from code DOSE25 applied at checkout, maintaining affordable access to this prescription-only medicine throughout their weight management journey. Our Ultimate Stability Trio offers three months of 2.4mg maintenance supply for £649.99, providing peace of mind for patients who have successfully reached their target dose. Each pen includes comprehensive patient information leaflets addressing common concerns including hair loss, supported by our GPhC-registered clinical team (#9012878) who monitor for any emerging safety signals throughout your treatment.
STEP Trial Safety Data: Wegovy And Hair Loss Monitoring
The STEP clinical trials provide the most comprehensive safety data regarding Wegovy and hair loss in over 4,500 patients studied across multiple international centres. In STEP 1, the largest trial involving 1,961 adults, hair loss events were carefully documented and found to be uncommon, affecting fewer than 2% of participants. The trial's robust safety monitoring included dermatological assessments and patient-reported outcomes, ensuring thorough documentation of any hair-related changes.
STEP 5, which followed patients for 104 weeks, provided crucial long-term safety data regarding Wegovy and hair loss concerns. The extended monitoring period demonstrated that hair changes, when they occurred, were typically transient and resolved without intervention as patients maintained their new weight. This evidence supports the MHRA's approval decision and ongoing Black Triangle monitoring programme, which continues to track safety signals including hair loss across the UK patient population.
How Wegovy Works: Understanding The Hair Loss Connection
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural fullness hormone produced in the intestines. By activating GLP-1 receptors in the brain's appetite centres, Wegovy reduces hunger signals and promotes feelings of satiety after smaller meals, leading to the substantial weight loss demonstrated in clinical trials. The medication works gradually through the dose escalation schedule, starting at 0.25mg weekly and increasing monthly until reaching the 2.4mg maintenance dose at week 17. This careful escalation helps minimise side effects while maximising weight loss effectiveness. The connection between Wegovy and hair loss is primarily related to the significant weight reduction achieved rather than direct follicular effects of semaglutide itself.
EverydayMeds Ordering Process: Addressing Wegovy Hair Loss Concerns
Our streamlined ordering process begins with a comprehensive 3-minute online clinical assessment that specifically asks about hair loss concerns and family history of androgenetic alopecia. Following submission, your assessment undergoes review by our qualified prescribers within 3 working days (or 24 hours with express service) who can address specific questions about Wegovy and hair loss risks. Once approved, your prescription-only medicine is dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our clinical team remains available throughout your treatment to monitor for any side effects including hair changes, ensuring rapid intervention if concerns arise. The assessment process also screens for conditions that might increase hair loss risk, allowing for personalised monitoring protocols tailored to your individual circumstances.
Storage And Practical Considerations: Managing Wegovy And Hair Loss Monitoring
Wegovy arrives in Novo Nordisk's FlexTouch pen format, requiring refrigeration at 2-8°C before first use but offering the convenience of 6 weeks storage at room temperature below 30°C once removed from the fridge. This storage flexibility allows for travel and reduces the risk of missed doses, which is crucial for maintaining the steady weight loss that minimises hair loss risk. The once-weekly injection schedule, combined with our patient monitoring system, ensures regular check-ins to assess progress and monitor for side effects including hair changes. Each pen contains four weekly doses, and our reminder system helps prevent dose delays that could trigger temporary hair shedding associated with treatment interruptions. The gradual dose escalation from 0.25mg to 2.4mg over 16 weeks allows your body to adjust progressively, potentially reducing the likelihood of gradual weight management-induced hair changes.
UK-Specific Wegovy And Hair Loss Monitoring: Black Triangle Status
The MHRA has designated Wegovy with Black Triangle status (▼), meaning additional monitoring for all side effects including hair loss to rapidly identify any emerging safety patterns in UK patients. This enhanced surveillance system requires healthcare providers to report all suspected adverse reactions, ensuring comprehensive post-market safety data collection beyond the clinical trials. EverydayMeds participates fully in this monitoring scheme, with our clinical team trained to identify and report hair loss events as part of our commitment to patient safety and regulatory compliance.
The Black Triangle monitoring specifically captures hair loss patterns that might not have been apparent in the controlled trial environment, providing real-world safety data across diverse UK patient populations. This ongoing surveillance has reinforced the clinical trial findings that hair loss with Wegovy remains uncommon and typically transient. Our GPhC registration (#9012878) ensures we maintain the highest standards of adverse event reporting, contributing to the collective understanding of Wegovy and hair loss relationships in clinical practice.
Next Steps: Starting Wegovy Despite Hair Loss Concerns
Don't let concerns about Wegovy and hair loss prevent you from accessing this clinically proven weight management treatment that has helped thousands of UK patients achieve substantial, sustained weight loss. Our clinical assessment specifically evaluates your individual risk factors for hair loss, including nutritional status, stress levels, and family history, allowing for personalised monitoring protocols. The evidence strongly suggests that any hair changes are temporary and related to weight loss rather than direct medication effects. Begin your consultation today using code FIRST40 for new customers or DOSE25 for returning patients, with prices starting from £79.99 for the essential starter dose. Visit https://everydaymeds.co.uk/collections/wegovy to access our comprehensive clinical assessment and join thousands of UK patients successfully managing their weight with proper medical supervision and monitoring for all potential side effects including hair loss.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
